Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation

Enregistré dans:

Détails bibliographiques
Publié dans:	Pharmaceuticals vol. 18, no. 8 (2025), p. 1157-1189
Auteur principal:	Niazi, Sarfaraz K
Publié:	MDPI AG
Sujets:	Food & Drug Administration > FDA United States > US Germany Monoclonal antibodies Product quality Collaboration Real time Batch processes Process controls Biological products Pharmaceutical industry Capital expenditures Batch processing Manufacturing Cost control 19th century Product testing
Accès en ligne:	Citation/Abstract Full Text + Graphics Full Text - PDF
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!